JAK2 and myeloid neoplasm: To further expand on the targeted therapy approach, we reference the study by Schwaab et al. (2015) which examined the efficacy of ruxolitinib, in treating myeloid neoplasms with PCM1::JAK2 and BCR::JAK2 fusion genes.